{
    "name": "glycerol phenylbutyrate",
    "comment": "Rx",
    "other_names": [
        "Ravicti"
    ],
    "classes": [
        "Urea Cycle Disorder Treatment Agents"
    ],
    "source": "https://reference.medscape.com/drug/ravicti-glycerol-phenylbutyrate-999807",
    "pregnancy": {
        "common": [
            "Limited available data to inform a drug-associated risk of major birth defects and miscarriage",
            "Report pregnancies to Horizon at 1-866-479-6742 "
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Administration to pregnant rabbits during organogenesis at ≥2.7 x the dose of 6.87 mL/m²/day resulted in maternal toxicity, but had no effects on embryo-fetal development",
                    "Administration to pregnant rats during organogenesis at ≥5.7 x the dose of 6.87 mL/m²/day resulted in maternal toxicity, reduced fetal weights, and variations in skeletal development; no adverse developmental effects were seen at 1.9 x the dose of 6.87 mL/m²/day"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human breast milk; because of the potential for serious adverse reactions, including neurotoxicity and tumorigenicity in a breastfed infant, advise patients that breastfeeding is not recommended"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to phenylbutyrate (eg, wheezing, dyspnea, coughing, hypotension, flushing, nausea, rash)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Safety and efficacy not established for N-acetylglutamate synthase (NAGS) deficiency",
                "Increased exposure to phenylacetate (PAA), the major metabolite, associated with neurotoxicity; if symptoms of vomiting, nausea, headache, somnolence, or confusion occur without high ammonia or other intercurrent illness which explains these symptoms, consider the potential for PAA neurotoxicity",
                "Low or absent pancreatic enzymes or intestinal disease resulting in fat malabsorption may result in reduced or absent digestion/absorption of glycerol phenylbutyrate"
            ],
            "specific": [
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Probenecid may inhibit renal excretion of glycerol phenylbutyrate metabolites including PAGN and PAA",
                        "Drugs that may affect plasma ammonia levels",
                        "Corticosteroids may cause breakdown of protein and increase plasma ammonia levels",
                        "Hyperammonemia may be induced by haloperidol or valproic acid",
                        "Potential for glycerol phenylbutyrate to affect other drugs",
                        "Glycerol phenylbutyrate is a weak inducer of CYP3A4",
                        "Coadministration may decrease systemic exposure to CYP3A4 substrates",
                        "Monitor for decreased efficacy of drugs with narrow therapeutic index (eg, alfentanil, quinidine, cyclosporine, midazolam)"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alfentanil",
            "description": {
                "common": "glycerol phenylbutyrate will decrease the level or effect of alfentanil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Monitor for decreased efficacy of CYP3A4 substrates that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betamethasone",
            "description": {
                "common": "betamethasone decreases effects of glycerol phenylbutyrate by Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels; monitor ammonia levels closely when glycerol phenylbutyrate is coadministered with corticosteroids."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "glycerol phenylbutyrate will decrease the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Monitor for decreased efficacy of CYP3A4 substrates that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clonidine",
            "description": {
                "common": "glycerol phenylbutyrate will decrease the level or effect of clonidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Monitor for decreased efficacy of CYP3A4 substrates that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "colchicine",
            "description": {
                "common": "glycerol phenylbutyrate will decrease the level or effect of colchicine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Monitor for decreased efficacy of CYP3A4 substrates that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cortisone",
            "description": {
                "common": "cortisone decreases effects of glycerol phenylbutyrate by Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels; monitor ammonia levels closely when glycerol phenylbutyrate is coadministered with corticosteroids."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "glycerol phenylbutyrate will decrease the level or effect of cyclosporine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Monitor for decreased efficacy of CYP3A4 substrates that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "dexamethasone decreases effects of glycerol phenylbutyrate by Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels; monitor ammonia levels closely when glycerol phenylbutyrate is coadministered with corticosteroids."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dihydroergotamine",
            "description": {
                "common": "glycerol phenylbutyrate will decrease the level or effect of dihydroergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Monitor for decreased efficacy of CYP3A4 substrates that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "disopyramide",
            "description": {
                "common": "glycerol phenylbutyrate will decrease the level or effect of disopyramide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Monitor for decreased efficacy of CYP3A4 substrates that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ergotamine",
            "description": {
                "common": "glycerol phenylbutyrate will decrease the level or effect of ergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Monitor for decreased efficacy of CYP3A4 substrates that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethosuximide",
            "description": {
                "common": "glycerol phenylbutyrate will decrease the level or effect of ethosuximide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Monitor for decreased efficacy of CYP3A4 substrates that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "everolimus",
            "description": {
                "common": "glycerol phenylbutyrate will decrease the level or effect of everolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Monitor for decreased efficacy of CYP3A4 substrates that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl",
            "description": {
                "common": "glycerol phenylbutyrate will decrease the level or effect of fentanyl by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Monitor for decreased efficacy of CYP3A4 substrates that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fludrocortisone",
            "description": {
                "common": "fludrocortisone decreases effects of glycerol phenylbutyrate by Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels; monitor ammonia levels closely when glycerol phenylbutyrate is coadministered with corticosteroids."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haloperidol",
            "description": {
                "common": "haloperidol decreases effects of glycerol phenylbutyrate by Other (see comment). Use Caution/Monitor. \nComment: Haloperidol may induce hyperammonemia; monitor ammonia levels closely when coadministered with glycerol phenylbutyrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "hydrocortisone decreases effects of glycerol phenylbutyrate by Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels; monitor ammonia levels closely when glycerol phenylbutyrate is coadministered with corticosteroids."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "methylprednisolone decreases effects of glycerol phenylbutyrate by Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels; monitor ammonia levels closely when glycerol phenylbutyrate is coadministered with corticosteroids."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam",
            "description": {
                "common": "glycerol phenylbutyrate will decrease the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Monitor for decreased efficacy of CYP3A4 substrates that have a narrow therapeutic index. Cmax and AUC were 25% and 32% lower for a single dose of midazolam after multiple doses of glycerol phenylbutyrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pimozide",
            "description": {
                "common": "glycerol phenylbutyrate will decrease the level or effect of pimozide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Monitor for decreased efficacy of CYP3A4 substrates that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prednisolone",
            "description": {
                "common": "prednisolone decreases effects of glycerol phenylbutyrate by Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels; monitor ammonia levels closely when glycerol phenylbutyrate is coadministered with corticosteroids."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prednisone",
            "description": {
                "common": "prednisone decreases effects of glycerol phenylbutyrate by Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels; monitor ammonia levels closely when glycerol phenylbutyrate is coadministered with corticosteroids."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "probenecid",
            "description": {
                "common": "probenecid, glycerol phenylbutyrate. decreasing renal clearance. Use Caution/Monitor. Probenecid may inhibit the renal excretion glycerol phenylbutyrate metabolites PAA and PAGN; caution when adjusting doses based on these metabolite levels."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinidine",
            "description": {
                "common": "glycerol phenylbutyrate will decrease the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Monitor for decreased efficacy of CYP3A4 substrates that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinine",
            "description": {
                "common": "glycerol phenylbutyrate will decrease the level or effect of quinine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Monitor for decreased efficacy of CYP3A4 substrates that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sirolimus",
            "description": {
                "common": "glycerol phenylbutyrate will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Monitor for decreased efficacy of CYP3A4 substrates that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "glycerol phenylbutyrate will decrease the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Monitor for decreased efficacy of CYP3A4 substrates that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "triamcinolone acetonide injectable suspension decreases effects of glycerol phenylbutyrate by Other (see comment). Use Caution/Monitor. \nComment: Corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels; monitor ammonia levels closely when glycerol phenylbutyrate is coadministered with corticosteroids."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triazolam",
            "description": {
                "common": "glycerol phenylbutyrate will decrease the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Monitor for decreased efficacy of CYP3A4 substrates that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valproic acid",
            "description": {
                "common": "valproic acid decreases effects of glycerol phenylbutyrate by Other (see comment). Use Caution/Monitor. \nComment: Valproic acid may induce hyperammonemia; monitor ammonia levels closely when coadministered with glycerol phenylbutyrate."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "celecoxib",
            "description": {
                "common": "glycerol phenylbutyrate decreases levels of celecoxib by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown. Glycerol phenylbutyrate does not significantly affect the pharmacokinetics of celecoxib, a substrate of CYP2C9. Cmax and AUC for celecoxib were 13% and 8% lower than after administration of celecoxib alone."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Neutropenia",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Constipation",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Pyrexia",
            "percent": null
        },
        {
            "name": "Hypophagia",
            "percent": null
        },
        {
            "name": "Cough",
            "percent": null
        },
        {
            "name": "nasal congestion",
            "percent": null
        },
        {
            "name": "Rhinorrhea",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Papule",
            "percent": null
        },
        {
            "name": "Gastroesophageal reflux",
            "percent": null
        },
        {
            "name": "Increased hepatic enzymes",
            "percent": null
        },
        {
            "name": "Feeding disorder",
            "percent": null
        },
        {
            "name": "decreased appetite",
            "percent": null
        },
        {
            "name": "hypophagia",
            "percent": null
        },
        {
            "name": "Anemia",
            "percent": null
        },
        {
            "name": "Cough",
            "percent": null
        },
        {
            "name": "Dehydration",
            "percent": null
        },
        {
            "name": "Metabolic acidosis",
            "percent": null
        },
        {
            "name": "Thrombocytosis",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "Lymphocytosis",
            "percent": null
        },
        {
            "name": "Flatulence",
            "percent": null
        },
        {
            "name": "Lethargy",
            "percent": null
        },
        {
            "name": "Irritability",
            "percent": null
        },
        {
            "name": "agitation",
            "percent": null
        }
    ]
}